Lyndra Therapeutics Valuation, Funding & Investors

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Dong-A ST Co Ltd is a Korea-based company principally engaged in the manufacturing and distribution of specialty pharmaceuticals. The company also involves in the provision of medical devices, diagnostic detection, as well as overseas sale business. Its in-house developed original drugs are used for gastritis treatment, erectile dysfunction treatment, functional dyspepsia, oxazolidinone class antibiotic, and diabetes treatment.

Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.

Goldfinch Biopharma is a biotechnology company developing therapies for chronic kidney disease through genetic target discovery. Its pipeline includes GFB-887, a small-molecule inhibitor of APOL1 in Phase 2 trials for APOL1-mediated kidney disease, and GFB-808 for focal segmental glomerulosclerosis. The Cambridge, Massachusetts-headquartered firm, founded in 2016, raised $110 million in Series B financing and collaborates with the Broad Institute on single-cell RNA sequencing of kidney tissues.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.

AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain, ranging from research and development to manufacturing and commercialization. The Vaccine products include Recombinant HBV Vaccines, Freeze-dried Human Rabies Vaccine, Inactivated HAV Vaccines, Group A, C, Y, and W135 MPSV, Bivalent Inactivated HFRS Vaccine, and Mumps Vaccine. It generates the majority of its revenues in the PRC.

Syncromune is a clinical-stage biopharmaceutical company developing Syncrovax, an in situ vaccine platform for metastatic solid tumors. It synchronizes tumor antigen release with immune cell activation using patient-specific antigens for personalized immunotherapy. Based in the United States, the firm advances combination therapies in oncology trials targeting melanoma and pancreatic cancer. syncromune.com details preclinical data showing T-cell optimization where checkpoint inhibitors fail.

Medipost Co Ltd is a Korea-based stem cell biotechnology company. The company is engaged in developing products to meet unmet medical needs. The company operates its business through four distinct segments: Stem Cell Therapeutics, Cord Blood Bank, Cosmetics, and Health Supplements. The Cord Blood Bank Division is involved in collecting and storing stem cells from the newborn's umbilical cord. The Stem Cell Therapeutics division manufactures allogeneic stem cell drug products. The Health Supplements division offers vitamins and nutritional supplements. The Cosmetics division is involved in the sales and marketing of natural cosmetics.

Acepodia Inc is a clinical stage biotechnology company engaged to develop first-in-class cell therapies by using the Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.

Orphazyme is a biopharmaceutical company focused on lysosomal storage diseases. The firm develops therapies emerging from research at the Danish Cancer Society, collaborating with institutions in Europe and the US. Copenhagen-based Orphazyme advances enzyme activators for genetic disorders.

Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company generates a majority of its revenue from USA, also operates in Taiwan too.

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.